$673.94K in average volume shows that Cytek BioSciences Inc (CTKB) is heading in the right direction

On Tuesday, Cytek BioSciences Inc (NASDAQ: CTKB) opened lower -0.83% from the last session, before settling in for the closing price of $6.02. Price fluctuations for CTKB have ranged from $3.80 to $12.31 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 36.02%. Company’s average yearly earnings per share was noted -77.78% at the time writing. With a float of $118.77 million, this company’s outstanding shares have now reached $130.71 million.

Considering the fact that the conglomerate employs 676 people, you should pay attention to its efficiency factor.

Cytek BioSciences Inc (CTKB) Insider Activity

A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Cytek BioSciences Inc is 9.22%, while institutional ownership is 60.17%. The most recent insider transaction that took place on Apr 09 ’24, was worth 13,304. In this transaction CHIEF TECHNOLOGY OFFICER of this company sold 1,900 shares at a rate of $7.00, taking the stock ownership to the 6,008,502 shares. Before that another transaction happened on Mar 19 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 20,000 for $6.71, making the entire transaction worth $134,200. This insider now owns 6,010,402 shares in total.

Cytek BioSciences Inc (CTKB) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of 9.92 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -77.78% per share during the next fiscal year.

Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators

Check out the current performance indicators for Cytek BioSciences Inc (CTKB). In the past quarter, the stock posted a quick ratio of 5.89. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.05. Likewise, its price to free cash flow for the trailing twelve months is 1239.68.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.16 in one year’s time.

Technical Analysis of Cytek BioSciences Inc (CTKB)

Compared to the last year’s volume of 0.75 million, its volume of 1.01 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 10.37%. Additionally, its Average True Range was 0.39.

During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 3.70%, which indicates a significant decrease from 12.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.39% in the past 14 days, which was lower than the 69.64% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $7.37, while its 200-day Moving Average is $7.35. Nevertheless, the first resistance level for the watch stands at $6.20 in the near term. At $6.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.61. If the price goes on to break the first support level at $5.78, it is likely to go to the next support level at $5.59. Should the price break the second support level, the third support level stands at $5.37.

Cytek BioSciences Inc (NASDAQ: CTKB) Key Stats

There are currently 130,824K shares outstanding in the company with a market cap of 781.00 million. Presently, the company’s annual sales total 193,020 K according to its annual income of -12,150 K. Last quarter, the company’s sales amounted to 58,230 K and its income totaled 5,500 K.